Jointly sponsored by the University of Cincinnati and Princeton CME

Target Audience

This activity is designed for hospital-based physicians, including cardiologists, hematologists, and oncologists, pharmacists, nurse practitioners, and physician assistants.

Learning Objectives

After completing this activity, participants should be able to:

• Describe the burden of venous thromboembolism (VTE) in the hospital and the potential impact of more widespread risk stratification and prophylaxis, particularly among medical patients
• List the Joint Commission/National Quality Forum (NQF) National Consensus Standards in development for the prevention and care of VTE
• Summarize the American College of Chest Physicians guidelines for the prevention and treatment of VTE
• Define the available antithrombin therapies and their benefits and limitations
• Implement the latest guidelines and recommendations to ensure compliance to the new Joint Commission/NQF standards for VTE prevention and care

Credit Eligibility

To be eligible for documentation of credit, all participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit. Those who mail or fax back their successfully completed post-test and evaluation form will receive documentation of credit by mail within 6 weeks.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release date: July 13, 2007; Expiration Date: July 13, 2008

Estimated time to complete: 1 hour

There is no fee associated with this activity.

CME Accreditation (Accepted for Physician Assistants)

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and Princeton CME. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

CPE Accreditation

Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 hour credit (0.1 CEU) of continuing pharmacy education (ACPE #452-999-07-014-H01).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Continuing Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.

AANP Accreditation

This program has been approved for 1.0 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0705222.

Grant Support

Supported by an educational grant from sanofi-aventis U.S.

Presenters

Scott Kaatz, DO, MSc, FACP
Senior Staff Physician
Associate Residency Program Director
Co-Director Anticoagulation Clinics
Henry Ford Hospital
Detroit, Michigan

Case Presenter

Edith Nutescu, PharmD
Clinical Associate Professor
University of Illinois at Chicago
College of Pharmacy and Medical Center
Chicago, Illinois

Independent Clinical Reviewer

D. Keith Payne, MD
Bryn Professor of Pulmonary Medicine
Louisiana State University
Health Sciences Center-Shreveport
Shreveport, Louisiana

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of the University of Cincinnati and Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Kaatz: Research Funding—Amgen (funds paid to Henry Ford Hospital), Boehringer-Ingelheim (funds paid to Henry Ford Hospital), sanofi-aventis U.S. (funds paid to Henry Ford Hospital); Consultant—Boehringer-Ingelheim, sanofi-aventis U.S.; Speaker—sanofi-aventis U.S.

Dr. Nutescu: Research Funding—GlaxoSmithKline (funds paid to the University of Illinois); Speaker—Eisai, sanofi-aventis U.S.

Dr. Payne: Research Funding—GlaxoSmithKline (funds paid to Louisiana State University Health Sciences Center), Paringenix, Inc (funds paid to Louisiana State University Health Sciences Center)

Planning Committee: Kay Weigand, University of Cincinnati; Randy Robbin and John Savage, Princeton CME; Mary Johnson, Princeton Media Associates have disclosed no relevant financial relationships with any commercial interests.

The University of Cincinnati and Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.

The following off-label/unapproved drugs or devices are discussed: outpatient treatment of pulmonary embolism with low-molecular-weight heparin.

Some of the clinical studies discussed in this activity may have been funded by manufacturers of drugs or devices.